Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLUS: Mirabegron in Men with OAB and BPH
NCT02757768Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 4, randomised, double-blind trial in overactive bladder (OAB) comparing Mirabegron with Placebo (2 arms). Primary endpoint: Change From Baseline to End of Treatment in Mean Number of Micturitions Per Day at 12 weeks. Started Jun 2016; status: completed.
02
Drugs
mirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02757768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02757768.